S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
S&P 500   4,330.00
DOW   34,070.42
QQQ   357.86
3 Compelling Reasons to Start Buying Undervalued Amazon
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares are mixed, Chinese markets surge, after latest retreat on Wall St
Analysts Recommend These Mining Stocks Before Metal Prices Rally
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
FedEx, Greenbrier rise; Cisco Systems, KB Home fall, Thursday, 9/21/2023
Turkey’s central bank hikes interest rates again in further shift in economic policies
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
The average long-term US mortgage rate edged up to 7.19% this week, slightly below its 2023 high
Renowned Federal Judge, 96, Faces Yearlong Suspension For Refusing to Retire
NASDAQ:ARWR

Arrowhead Pharmaceuticals (ARWR) Stock Forecast, Price & News

$27.23
+0.22 (+0.81%)
(As of 09/21/2023 ET)
Compare
Today's Range
$26.51
$27.63
50-Day Range
$26.84
$36.08
52-Week Range
$23.09
$42.48
Volume
790,164 shs
Average Volume
949,604 shs
Market Capitalization
$2.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.53

Arrowhead Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.69 Rating Score
Upside/​Downside
100.3% Upside
$54.53 Price Target
Short Interest
Bearish
6.25% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.55
Upright™ Environmental Score
News Sentiment
0.32mentions of Arrowhead Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$2.59 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.67) to ($2.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

348th out of 965 stocks

Pharmaceutical Preparations Industry

148th out of 453 stocks


ARWR stock logo

About Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

ARWR Price History

ARWR Stock News Headlines

The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Chardan Capital Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
ARWR - Arrowhead Pharmaceuticals, Inc.
Arrowhead: Biotech Innovation On Display
See More Headlines
Receive ARWR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ARWR Company Calendar

Last Earnings
8/07/2023
Today
9/22/2023
Fiscal Year End
9/30/2023
Next Earnings (Estimated)
11/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARWR
Employees
397
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.53
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+100.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.69
Research Coverage
16 Analysts

Profitability

Net Income
$-176,060,000.00
Pretax Margin
-70.12%

Debt

Sales & Book Value

Annual Sales
$256.21 million
Book Value
$3.95 per share

Miscellaneous

Free Float
101,833,000
Market Cap
$2.92 billion
Optionable
Optionable
Beta
1.00
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Christopher R. Anzalone Ph.D. (Age 54)
    CEO, Pres & Director
    Comp: $1.65M
  • Mr. Kenneth A. MyszkowskiMr. Kenneth A. Myszkowski (Age 57)
    Chief Financial Officer
    Comp: $761.55k
  • Mr. Patrick O'Brien J.D. (Age 59)
    PharmD, COO, Gen. Counsel & Sec.
    Comp: $749.86k
  • Dr. James C. Hamilton M.D. (Age 45)
    MBA, Chief of Discovery & Translational Medicine
    Comp: $676.81k
  • Ms. Tracie Oliver
    Chief Commercial Officer
  • Dr. Mark M. Davis Ph.D.
    Founder and Founder & Director of Insert Therapeutics Inc & Calando
  • Dr. Vincent Anzalone CFA
    Head of Investor Relations & VP
  • Mr. Howard Lovy
    Director of Communications
  • Dr. Mark Seefeld (Age 69)
    Head of Toxicology & VP
  • Dr. Javier San Martin M.D. (Age 58)
    Chief Medical Officer













ARWR Stock - Frequently Asked Questions

Should I buy or sell Arrowhead Pharmaceuticals stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arrowhead Pharmaceuticals in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARWR shares.
View ARWR analyst ratings
or view top-rated stocks.

What is Arrowhead Pharmaceuticals' stock price forecast for 2023?

16 Wall Street analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' stock. Their ARWR share price forecasts range from $27.00 to $90.00. On average, they expect the company's share price to reach $54.53 in the next twelve months. This suggests a possible upside of 100.3% from the stock's current price.
View analysts price targets for ARWR
or view top-rated stocks among Wall Street analysts.

How have ARWR shares performed in 2023?

Arrowhead Pharmaceuticals' stock was trading at $40.56 at the beginning of the year. Since then, ARWR shares have decreased by 32.9% and is now trading at $27.23.
View the best growth stocks for 2023 here
.

When is Arrowhead Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 27th 2023.
View our ARWR earnings forecast
.

How were Arrowhead Pharmaceuticals' earnings last quarter?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its quarterly earnings results on Monday, August, 7th. The biotechnology company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $0.38. The biotechnology company had revenue of $15.83 million for the quarter, compared to analyst estimates of $45.42 million. Arrowhead Pharmaceuticals had a negative trailing twelve-month return on equity of 42.79% and a negative net margin of 69.38%. The business's revenue for the quarter was down 51.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.68) EPS.

What other stocks do shareholders of Arrowhead Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP), Bank of America (BAC), Tesla (TSLA), Salesforce (CRM) and Advanced Micro Devices (AMD).

What is Arrowhead Pharmaceuticals' stock symbol?

Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."

Who are Arrowhead Pharmaceuticals' major shareholders?

Arrowhead Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.95%), State Street Corp (5.14%), JPMorgan Chase & Co. (2.69%), Geode Capital Management LLC (2.01%), Credit Suisse AG (1.33%) and Northern Trust Corp (1.21%). Insiders that own company stock include Adeoye Y Olukotun, Backer Marianne De, Christopher Richard Anzalone, Douglas B Given, Douglas B Given, James C Hamilton, James Hassard, Kenneth Allen Myszkowski, Martin Javier San, Mauro Ferrari, Patrick O'brien, Tracie Oliver and William D Waddill.
View institutional ownership trends
.

How do I buy shares of Arrowhead Pharmaceuticals?

Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arrowhead Pharmaceuticals' stock price today?

One share of ARWR stock can currently be purchased for approximately $27.23.

How much money does Arrowhead Pharmaceuticals make?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a market capitalization of $2.92 billion and generates $256.21 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

How many employees does Arrowhead Pharmaceuticals have?

The company employs 397 workers across the globe.

How can I contact Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals' mailing address is 177 E. Colorado Blvd Suite 700, Pasadena CA, 91105. The official website for the company is www.arrowheadpharma.com. The biotechnology company can be reached via phone at (626) 304-3400, via email at ir@arrowheadpharma.com, or via fax at 626-304-3401.

This page (NASDAQ:ARWR) was last updated on 9/22/2023 by MarketBeat.com Staff

My Account -